Key Drivers
- Strong Liquidity
- Weak Operating Profit
- Improving Cash Flow
AIAI Summary
ZVRA has meaningfully re-rated from a development biotech to a cash-generating rare-disease franchise with 95% gross margins and a strong balance sheet, but the stock already prices in much of the good news, so upside now depends on sustained MIPLYFFA growth, confirmed patent protection, and evidence that the business can diversify beyond a single product.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Weak Operating Profit
- •Improving Cash Flow
ZVRA's latest quarter showed strong sales, 95% gross margins, abundant liquidity, and low leverage with improving cash flow, but the full-year picture still reflects weak core operating profitability and a large retained-earnings deficit.
Price Behavior
Key Price Behavior Insights:
- •Higher-high trend
- •Extended rally
- •Breakout holding
ZVRA remains in a short-term uptrend with higher highs/lows and a strong breakout held over the last month, but it is now extended and needs to clear $14.34 to keep momentum while holding $13.50 as support.
Sharp breakout in early
Sentiment & News
Key News Insights:
- •Patent protection
- •Pediatric safety
- •CMO transition
Zevra's June updates reinforce MIPLYFFA's long-term exclusivity and supportive pediatric safety data, while a planned CMO transition is the main near-term organizational change.
The news is modestly positive for Zevra's outlook as it strengthens MIPLYFFA's commercial moat and clinical profile, though the leadership change could create some short-term execution risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings